Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bavituximab plus docetaxel in advanced breast cancer
NCT00669591Phase 2Completed
- Sponsor
- Avid Bioservices, Inc.
- Start
- Jan 2008
- Primary completion
- Jun 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bavituximab in breast cancer, sponsored by Avid Bioservices, Inc. Primary endpoint: Overall Response Rate at 1 year. Started Jan 2008; status: completed.
02
Drugs
bavituximab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00669591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00669591.